Slides
Page 1
Note : This document has been translated from the Japanese original for reference purposes only . In the event of any discrepancy between this translated document and the Japanese original , the original shall prevail . Total commitment to good health Kyoso Mirai Financial Highlights for the Three Months Ended June 30 , 2026 August 5 , 2026 ( Wed ) © TOHO HOLDINGS CO . , LTD . All rights reserved G. TOHO HOLDINGS CO.LTD .
Page 2
2 © TOHO HOLDINGS CO.,LTD. All rights reserved Profit and Loss Statement (Consolidated) Three months ended June 30, 2025 Three months ended June 30, 2026 Results % of net sales Results % of net sales YoY change (%) Net sales 375,813 397,774 5.84 Gross profit 30,060 8.00 29,479 7.41 -1.93 SG&A 26,217 6.98 27,013 6.79 3.04 Operating profit 3,842 1.02 2,465 0.62 -35.84 Ordinary profit 4,436 1.18 3,810 0.96 -14.11 Net profit* 3,353 0.89 2,355 0.59 -29.76 Summary： • Implemented a 4.02% NHI drug price reduction on a drug price basis due to the April drug price revision • Formulated the Medium-term Management Plan 2026-2028 “Soaring into the Next Generation,” covering a three-year period from FY2026 （Unit: million Yen） *Profit attributable to owners of parent
Page 3
3 © TOHO HOLDINGS CO.,LTD. All rights reserved Profit and Loss Statement (Pharmaceutical Wholesaling Business) Three months ended June 30, 2025 Three months ended June 30, 2026 Results % of net sales Results % of net sales YoY change (%) Net sales 362,029 384,570 6.23 Gross profit 20,542 5.67 20,090 5.22 -2.20 SG&A 16,386 4.53 16,979 4.42 3.62 Operating profit 4,155 1.15 3,110 0.81 -25.15 Summary： • Continued sales growth of cancer drugs and limited-handling products for selected wholesalers, such as specialty pharmaceuticals • Gross profit and operating profit declined due to rising pharmaceutical purchase costs • Sales of COVID-19 drugs and reagents declined (down 68.2 % year-on-year) （Unit: million Yen）
Page 4
4 © TOHO HOLDINGS CO.,LTD. All rights reserved Composition of Sales by Category and Contract Rate April 2025-June 2025 April 2026-June 2026 Innovative drugs 40.7% 46.3% Patented drugs, others 39.9% 38.7% Long-listed original drugs 10.4% 5.8% Generic drugs 8.9% 9.2% ＜Composition of sales by category＞ 2024/6 2025/6 2026/6 Value Basis 13.2% 12.9% 10.8% ＜Contract rate＞
Page 5
5 © TOHO HOLDINGS CO.,LTD. All rights reserved Profit and Loss Statement (Dispensing Pharmacy Business) Three months ended June 30, 2025 Three months ended June 30, 2026 Results % of net sales Results % of net sales YoY change (%) Net sales 24,619 24,977 1.45 Gross profit 8,653 35.15 8,654 34.65 0.01 SG&A 8,468 34.40 8,541 34.20 0.86 Operating profit 184 0.75 113 0.45 -38.59 Summary： • Operating profit declined due to a decrease in the number of patient visits resulting from an increase in long-term prescriptions • Strengthened initiatives in home healthcare, including the assignment of pharmacists specializing in home care • Promoted digital transformation (DX) in healthcare through the installation of dispensing robots and automated check-in kiosks, and the introduction of AI-powered medication history systems （Unit: million Yen）
Page 6
6 © TOHO HOLDINGS CO.,LTD. All rights reserved Investments and alliances aimed at creating new businesses Medium-term Management Plan 2026-2028 “Soaring into the Next Generation” Company Name Details of Alliances April Metaphore Biotechnologies Inc. A U.S. next-generation antibody drug discovery company utilizing AI technology; the first investment by the CVC fund “TOHO Ventures” May Kyowa Medical Corporation Signed a memorandum of understanding on joint research aimed at strengthening SPD functions for pharmaceuticals and medical supplies and developing solutions for medical institutions in the Tokai region June DHL Supply Chain Japan, Inc. Signed a memorandum of understanding on collaboration to provide comprehensive logistics solutions in Japan June Rege Nephro Co., Ltd. Invested in a bio-venture company conducting R&D on kidney regenerative medicine and drug discovery using iPS cells, in order to support its R&D activities
Page 7
7 © TOHO HOLDINGS CO.,LTD. All rights reserved Making Ishin Pharma Co., Ltd. a Subsidiary Medium-term Management Plan 2026-2028 “Soaring into the Next Generation” A biotech venture founded in September 2008 that developed “AloStem® Sheet,” a regenerative medical product for the treatment of epidermolysis bullosa, a designated intractable genetic chronic skin disease AloStem® Sheet The world’s first regenerative medical product derived from human (allogeneic) adipose-derived mesenchymal stem cells, indicated for dystrophic, junctional, and simplex (limited to severe generalized type) epidermolysis bullosa* * : Indicated for patients with dystrophic, junctional, and simplex (limited to severe generalized type) epidermolysis bullosa who have intractable or recurrent erosions/ulcers. Applied to intractable or recurrent erosion/ulcer sites to promote re-epithelialization. Established a Group full-line service system, with KYOSOMIRAI PHARMA handling shipment approval, and TOHO PHARMACEUTICAL and its pharmaceutical wholesale subsidiaries managing the distribution process under strict temperature control
Page 8
8 © TOHO HOLDINGS CO.,LTD. All rights reserved Progress of the Medium-Term Management Plan Medium-term Management Plan 2026-2028 “Soaring into the Next Generation” Measure Progress Growth Strategy Increasing gross profit in our Pharmaceutical Wholesaling business • Identified key challenges related to securing specialty pharmaceuticals and focusing on growth-driving products, and have begun implementing a new PDCA cycle to address these challenges. Efficiency Strategy Reduction of indirect material costs • Identified products and services that could help reduce costs and reviewed our business partners and contracts. • Exploring ways to improve productivity in our transportation and delivery operations, and promote measures with clearly specified cost savings. Business process reform • Implementing specific measures, starting with back-office operations. Strengthening the Management Foundation HR system reform • Progress is being made on the overhaul of our core human resources system, and we plan to complete the transition to the new system during the second quarter. Corporate culture reform • Based on the results of the engagement survey, we are promoting the development and implementation of measures to create a better work environment across all companies and departments.
Page 9
© TOHO HOLDINGS CO.,LTD. All rights reserved Total commitment to good health [Front office in charge of IR] Corporate Strategy Division E-mail: info@so.tohoyk.co.jp https://www.tohohd.co.jp/en [Notice] Statements contained in this presentation that are not past facts are forward-looking statements that reflect our plans, expectations, strategies and assumptions, and involve known and unknown risks and uncertainties. These statements are based on currently available information and represent the beliefs of the management of T OHO HOLDINGS CO.,LTD. These statements are subject to numerous risks and uncertainties that could cause actual results, performance and achievements to differ materially from those described or impl ied in the forward-looking statements. Since many factors could cause the actual results to differ substantially from these forward-looking statements, investors are advised to avoid undue reliance on the latter. This presentation has not been prepared for the purpose of stimulating investment. Any decision to invest is the sole responsibility of the individual investor. In addition, the information about the pharmaceutical products included in the document is not a thing aimed for advertising and medical advice.